MongoliaTuberculosis profile
Population  2014 2.9 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.064 (0.059–0.07) 2.2 (2–2.4)
Mortality (HIV+TB only) <0.01 (<0.01–<0.01) 0.07 (0.05–0.09)
Prevalence  (includes HIV+TB) 6.6 (3–12) 227 (101–402)
Incidence  (includes HIV+TB) 5 (4.3–5.6) 170 (149–193)
Incidence (HIV+TB only) 0.011 (<0.01–0.012) 0.37 (0.31–0.42)
         
Case detection, all forms (%) 90 (80–100)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 1.4 (0.7–2.5) 34 (29–38)
MDR-TB cases among notified pulmonary
TB cases
35 (17–62) 190 (160–210)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 1 791   241
Pulmonary, clinically diagnosed 676   24
Extrapulmonary 1 705   46
       
Total new and relapse 4 483    
Previously treated, excluding relapses 288    
Total cases notified 4 771    
Among 4 483 new and relapse cases:
389 (9%) cases aged under 15 years; male:female ratio: 1.3
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 1 043 (58%) 1 664 (278%) 2 956
Laboratory-confirmed RR-/MDR-TB cases     318
Patients started on MDR-TB treatment ***     294
TB/HIV 2014 Number (%)
TB patients with known HIV status 3 498 (73)
HIV-positive TB patients 8 (<1)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 6 (75)
HIV-positive TB patients on antiretroviral therapy (ART) 6 (75)
HIV-positive people screened for TB 150  
HIV-positive people provided with IPT 0  
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (89) 4 220
Previously treated cases, excluding relapse, registered in 2013 (79) 395
HIV-positive TB cases, all types, registered in 2013 (60) 5
RR-/MDR-TB cases started on second-line treatment in 2012 (61) 179
XDR-TB cases started on second-line treatment in 2012   0
Laboratories 2014  
Smear (per 100 000 population) 1.3
Culture (per 5 million population) 3.4
Drug susceptibility testing (per 5 million population) 1.7
Sites performing Xpert MTB/RIF 3
Is second-line drug susceptibility testing available? Yes, in and outside
country
Financing TB control 2015  
National TB programme budget (US$ millions) 5.3
% Funded domestically 50%
% Funded internationally 50%
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-05-05 Data: www.who.int/tb/data